Related Experiment Video
Updated: Jun 10, 2026

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
Published on: August 12, 2019
[Clinical studies on pramipexol retard]
Péter Klivényi1, László Vécsei
1Szegedi Tudományegyetem, Neurológiai Klinika, Szeged. klivenyi@nepsy.szote.u-szeged.hu
Abstract:
Pramipexol retard is the newest drug for the treatment of Parkinson's disease. The prolonged release of the agent in this preparation allows a more continuous dopaminergic stimulation than previous preparations, without reducing the agent's already known and proven clinical efficiency. In addition, it has a more favourable adverse effect profile than previous preparations, and patient compliance can also be better as it needs to be taken only once daily. These benefits have been proven in recent clinical studies, of which the most important ones are reviewed here.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Preclinical Development: Overview
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Pharmacodynamics in Geriatric Patients: Effects of Age
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
